Advertisement


Jane McNeil Beith, MD, PhD, on Reducing Fear in Cancer Survivors

2017 ASCO Annual Meeting

Advertisement

Jane McNeil Beith, MD, PhD, of Chris O’Brien Lifehouse, discusses long-term study results on a psychological intervention, called “Conquer Fear,” designed to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Abstract LBA10000)



Related Videos

Supportive Care

Viviane Hess, MD, on Managing Stress in Newly Diagnosed Patients

Viviane Hess, MD, of the University of Basel and University Hospital Basel, discusses a Web-based stress management tool, called STREAM, designed to reduce stress and improve quality of life for newly diagnosed cancer patients, who often lack psychological support. (Abstract LBA10002)

Hepatobiliary Cancer

Ann-Lii Cheng, MD, PhD, on Hepatocellular Carcinoma: Trial Results on Lenvatinib vs Sorafenib

Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)

Colorectal Cancer

John Marshall, MD, and Qian Shi, PhD, on Colon Cancer: Results of the IDEA Trial

John Marshall, MD, of Georgetown University, and Qian Shi, PhD, of the Mayo Clinic, discuss study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Kidney Cancer

Bernard J. Escudier, MD, and Sumanta K. Pal, MD, on RCC: Trial Results on Sunitinib

Bernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to treat high-risk renal cell carcinoma, which validate the 16-gene Recurrence Score in patients with stage III disease. (Abstract 4508)

Gynecologic Cancers

Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)

Advertisement

Advertisement




Advertisement